High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017

Total Page:16

File Type:pdf, Size:1020Kb

Load more

High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017 Disease / Therapeutic Category High-Cost Non-Formulary Generics Lower Cost Generic Formulary Alternatives Acne Adapalene 0.1% Lotion Adapalene 0.1% Cream Adapalene 0.3% Gel Pump Tretinoin 0.05% Cream Tretinoin Gel Micro 0.04% Pump Tretinoin 0.05% Emollient Cream Tretinoin Gel Micro 0.1% Pump Tretinoin 0.025% Gel Tretinoin Gel Micro 0.04% Tube Tretinoin 0.025% Cream Tretinoin Gel Micro 0.1% Tube Tretinoin 0.01% Gel Tretinoin 0.05% Gel OTC Adapalene 0.1% Gel (OTC Products Not Covered) Clindamycin Phosphate Foam Clindamycin Phosphate Solution Clindamycin Phosphate 1% Gel Clindamycin Phosphate/Benzoyl Peroxide Gel or Gel Clindamycin Solution & OTC Benzoyl Peroxide (OTC Pump Products Not Covered) Clindamycin Phosphate 1% Gel Erythromycin-Benzoyl Gel Erythromycin Topical Solution Erythromycin Topical Soln & OTC Benzoyl Peroxide (OTC Products Not Covered) Sulfacetamide Sodium/Sulfur Medicated Pads Clindamycin Phosphate Solution Sulfacetamide Sodium/Sulfur Suspension Erythromycin Topical Solution Sulfacetamide Sodium/Sulfur Lotion Sulfacetamide Sodium 10% Suspension Sulfacetamide Sodium/Sulfur 10 %-5 % Foam Erythromycin Topical Gel Erythromycin Topical Solution Clindamycin/Tretinoin Gel Clindamycin Phosphate Gel 1% & Tretinoin 0.025% Gel Benzoyl Peroxide 4% Gel Benzoyl Peroxide 5% Gel Benzoyl Peroxide 8% Gel Benzoyl Peroxide 10% Gel Benzoyl Peroxide 6 % Towelette OTC Benzoyl Peroxide Wash (OTC Products Not Covered) Copyright © 2016 MedImpact, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017 Disease / Therapeutic Category High-Cost Non-Formulary Generics Lower Cost Generic Formulary Alternatives ADHD/Narcolepsy Amphetamine/Dextroamphetamine ER Capsule Mixed Amphetamines IR Tablet Dexmethylphenidate ER Capsule Methylphenidate IR Tablet Dextroamphetamine ER Capsule Dexmethylphenidate IR Tablet Dextroamphetamine Tablet Methamphetamine Tablet Methylphenidate ER Capsule (Metadate CD) Methylphenidate ER Capsule (Ritalin LA) Methylphenidate ER Tablet (Concerta) Methylphenidate HCL Tablet ER (Metadate ER) Allergies Budesonide Nasal Spray OTC Fluticasone Nasal Spray (Flonase)- (OTC Products Olopatadine Nasal Spray Not Covered) Mometasone Nasal Spray OTC Azelastine Nasal Spray (Astelin) - (OTC Products Not Covered) OTC Traimcinolone Nasal Spray (Nasacort) - (OTC Products Not Covered) OTC Budesonide Nasal Spray (Rhinocort Allergy) - (OTC Products Not Covered) Desloratadine ODT OTC Loratadine (OTC Products Not Covered) OTC Cetirizine (OTC Products Not Covered) OTC Fexofenadine (OTC Products Not Covered) Zafirlukast Tablet Monteleukast Tablet Montelukast Chewable Tablet Fexofenadine-PSE Combo Tablet (Allegra D 24 Hour) OTC Fexofenadine & OTC Pseudoephedrine (OTC Products Not Covered) Alzheimer's Disease Donepezil 23 mg Tablet Donepezil 10 mg Tablet Angina Nitroglycerin Translingual Spray Nitroglycerin Sublingual Tablet Antibiotics Amoxicillin/Clavulanate ER Tablet Amoxicillin/Clavulanate IR Tablet Doxycycline Hyclate 75 mg Delayed Release Tablet Doxycycline Monohydrate 75 mg Tablet Doxycycline Monohydrate 75 mg Capsule Copyright © 2016 MedImpact, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017 Disease / Therapeutic Category High-Cost Non-Formulary Generics Lower Cost Generic Formulary Alternatives Doxycycline Hyclate 100 mg Delayed Release Tablet Doxycycline Monohydrate 100 mg Capsule Doxycycline Hyclate 100mg Tablet Doxycycline Hyclate 150 mg Delayed Release Tablet Doxycycline Monohydrate 150 mg Tablet Doxycycline Monohydrate 150 mg Capsule Doxycycline Monohydrate 40 mg Capsule, Biphasic Doxycycline Monohydrate 50 mg Capsule Release Doxycycine Hyclate 20 mg Tablet (Two Tablets) Doxycycline Monohydrate 50 Mg Tablet Minocycline ER Tablet Minocycline Capsule Minocycline IR Tablet Doxycycline Hyclate 200mg Delayed Tablet Doxycycline Hyclate 100mg Tablet Doxycycline Hyclate 50mg Delayed Tablet Doxycycline Hyclate 50 mg Capsule Clarithromycin 500 mg ER Tablet Clarithromycin IR Tablets (250mg, 500 mg) Antifungals, oral Griseofulvin Ultramicrosize Tablet Terbinafine Tablet Griseofulvin Microsize Tablet Ketoconazole Tablet Voriconazole Tablet Itraconazole Tablet Antiprotozoal Tinidazole Tablet Metronidazole Tablet/Capsule Clindamycin Capsule Chloroquine Tablet Antipsychotics Olanzapine ODT Olanzapine Tablet Olanzapine/Fluoxetine Combination Capsule Olanzapine Tab & Fluoxetine Capsule Risperidone ODT Risperidone Tablet Aripiprazole ODT Aripiprazole Tablet Fluphenazine HCL Tablet Risperidone Tablet Haloperidol Tablet Paliperidone Tab ER Tablet Quetiapine Tablet Risperidone Tablet Olanzapine Tablet Aripiprazole Tablet Anxiety Alprazolam ODT Alprazolam Tablet Copyright © 2016 MedImpact, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017 Disease / Therapeutic Category High-Cost Non-Formulary Generics Lower Cost Generic Formulary Alternatives Meprobamate Tablet Buspirone Tablet Asthma Levalbuterol Inhalation Solution Albuterol Inhalation Solution Carbonic Anhydrase Inhibitors Methazolamide Tablet Acetazolamide ER 500mg Capsule Acetazolamide IR Tablet Corticosteroids, Topical Low Potency Desonide 0.05% Cream [Low] Alclometasone Diprop 0.05% Cream [Low] Fluocinolone 0.01% Cream [Low] Triamcinolone Acet 0.025% Cream [Low] Desonide 0.05% Lotion [Low] Betamethasone Val 0.025% Lotion [Low] Triamcinolone Acet 0.025% Lotion [Lower-Mid] Fluocinolone Acetonide 0.01% Soln [Low] Mometasone Furoate 0.1% Solution [Medium] Corticosteroids, Topical Medium/Low Clocortolone Pivalate 0.1% Cream [Medium] Mometasone Furoate 0.1% Cream [Medium] to Medium Potency Desoximetasone 0.05% Cream [Medium] Triamcinolone Acetonide 0.1% Cream [Medium] Triamcinolone/Dimethicone 0.1%-5% Kit [Medium] Desonide 0.05% Ointment [Lower-Mid] Fluocinolone Acetonide 0.025% Ointment [Medium] Desoximetasone 0.05% Ointment [Medium] Triamcinolone Acetonide 0.025% Ointment[Lower- Hydrocortisone Butyrate 0.1% Ointment [Lower-Mid] Mid] Hydrocortisone Valerate 0.2% Ointment [Medium] Triamcinolone Acetonide 0.1% Ointment [Medium] Triamcinolone Absorbase 0.05% Ointment [Medium] Fluticasone 0.05% Lotion [Lower-Mid] Fluticasone Prop 0.05% Cream [Lower-Mid] Hydrocortisone Butyrate 0.1% Solution [Lower-Mid] Triamcinolone Acet 0.1% Lotion [Lower-Mid] Mometasone Furoate 0.1% Solution [Medium] Hydrocortisone Butyrate 0.1% Lipo Cream [Lower- Betamethasone Valerate 0.1% Cream [Lower-Mid] Mid] Fluocinolone Acetonide 0.025% Cream [Lower-Mid] Hydrocortisone Butyrate 0.1% Cream [Lower-Mid] Fluticasone Prop 0.05% Cream [Lower-Mid] Hydrocortisone Valerate 0.2% Cream [Lower-Mid] Flurandrenolide 0.05% Cream [Lower-Mid] Triamcinolone Topical Spray [Medium] Mometasone Furoate 0.1% Solution [Medium] Triamcinolone Acetonide 0.1% Cream [Medium] Triamcinolone Acetonide 0.1% Ointment [Medium] Copyright © 2016 MedImpact, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. High-Cost Generics and Formulary Alternatives Reference Effective Date: July 1, 2017 Disease / Therapeutic Category High-Cost Non-Formulary Generics Lower Cost Generic Formulary Alternatives Corticosteroids, Topical Super Amcinonide 0.1% Cream [High] Betamethasone Diprop 0.05% Cream [High] High/High Potency Diflorasone Diacetate 0.05% Cream [High] Betamethasone Dipropionate Augmented 0.05% Cream [High] Desoximetasone 0.25% Cream [High] Fluocinonide 0.05% Cream [High] Fluocinonide 0.05% Emollient Cream [High] Triamcinolone Acetonide 0.05% Cream [High] Amcinonide 0.1% Ointment [High] Betamethasone Dipropionate 0.05% Ointment [High] Desoximetasone 0.25% Ointment [High] Betamethasone Valerate 0.1% Ointment [High] Diflorasone
Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E

    Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E

    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al

    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic

    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
  • Orange Book Cumulative Supplement 7 July 2006

    Orange Book Cumulative Supplement 7 July 2006

    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
  • Fluoxymesterone-Dea Schedule Iii Androfluorene

    Fluoxymesterone-Dea Schedule Iii Androfluorene

    Cat. No. F7751 FLUOXYMESTERONE--DEA SCHEDULE III ANDROFLUORENE Androgen. OH Mol. Formula: C20H29FO3 HO H3C CH3 Mol. Wt.: 336.45 (anhyd.) F H3C m.p.: 288-290°C CAS Registry No.: 76-43-7 O Chemical Name: 4-Androsten-9a-fluoro-17a-methyl-11b,17b-diol-3-one 22 Physical Properties: White photosensitive solid. [a] D = +102.34° (c = 0.47, EtOH). Caution: Due care should be exercised to prevent skin contact, ingestion or inhalation of this compound. Storage: Store tightly sealed at room temperature, protected from exposure to light. Solubility: Soluble in ethanol (7.3 mg/ml) or water (< 0.5 mg/ml). Solubility in 45% aqueous (w/v) 2-hydroxypropyl-b- cyclodextrin (Cat. No. H-107): 6.4 mg/ml. Disposal: Dissolve or mix the compound with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. This product is controlled by the Drug Enforcement Administration. Appropriate security must be maintained until the substance is destroyed. Records must be kept which detail the ultimate disposition of the material. References: 1. Merck Index 11th Ed., No. 4113. 2. Saborido, A., Vila, J., Molano, F., Megias, A. “Effect of steroids on mitochondria and sarcotubular system of skeletal muscle.” J. Appl. Physiol. 70(3), 1038 (1991). 3. Fernandez, L., Chirino, R., Boada, L.D., Navarro, D., Cabrera, N., del Rio, I., Diaz-Chico, B.N. “Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes.” Endocrinology 134(3), 1401 (1994). CONTROLLED SUBSTANCE - DEA LICENSE REQUIRED (III) Rev.
  • Steroids Topical

    Steroids Topical

    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
  • Formulary Updates Effective January 1, 2021

    Formulary Updates Effective January 1, 2021

    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
  • Australian Public Assessment Report for Clobetasol Propionate

    Australian Public Assessment Report for Clobetasol Propionate

    Australian Public Assessment Report for Clobetasol propionate Proprietary Product Name: Clobex Sponsor: Galderma Australia Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Medication List

    Medication List

    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE